Pharmaceutical Investing U.S. Food and Drug Administration Approves Updated Indication Statement for RINVOQ® for the Treatment of Inflammatory Bowel Disease
Pharmaceutical Investing AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors
Pharmaceutical Investing SkinMedica® Debuts Reimagined Packaging and Unveils New HA5® Hydra Collagen Water Burst Moisturizer
Pharmaceutical Investing AbbVie Announces Positive Topline Results from Phase 2 ELATE Trial Evaluating OnabotulinumtoxinA for the Treatment of Upper Limb Essential Tremor
Pharmaceutical Investing AbbVie Begins Construction on $70 Million Expansion to Further Increase Biologics Manufacturing and R&D Presence in the U.S.
Pharmaceutical Investing AbbVie Submits Biologics License Application to U.S. FDA for Pivekimab sunirine - an Investigational Antibody-Drug Conjugate to Treat Rare Cancer with Limited Treatment Options
Pharmaceutical Investing AbbVie Breaks Ground on New North Chicago Active Pharmaceutical Ingredient Manufacturing Facility
Pharmaceutical Investing AbbVie Submits New Drug Application to U.S. FDA for Tavapadon for the Treatment of Parkinson's Disease
Pharmaceutical Investing QULIPTA® Now Publicly Reimbursed in Quebec for Chronic Migraine and CGRP Class Review Published
Pharmaceutical Investing Allergan Aesthetics to Showcase Multimodal Treatment Approach and Continued Commitment to Skin Quality at AMWC Dubai
Pharmaceutical Investing Allergan Aesthetics Announces Expansion of SKINVIVE by JUVÉDERM® into 35 New Markets, Reinforcing its Commitment to Advancing Global Skin Quality
Finlay Minerals Announces Closing of Non-Brokered Private Placement of Flow-Through and Non-Flow-Through Units
